

VPA10774/074/001

DACLOTRIX 200 mg/40 mg spot-on solution for dogs up to 4 kg

Variation	Summary	Date
Vet - B3 a)	VNRA - Vet - B3 a) - - Vet - B3 a) - Changes to the quality part of the dossier - Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for importation, manufacturer responsible for batch release, site where batch control takes place, or supplier of (1) a starting material for an active substance, (2) a reagent or (3) an excipient (when mentioned in the dossier)	20/08/25
Vet - A1 e)	VNRA - Vet - A1 e) - - Vet - A1 e) Administrative changes - Change in the name or address of a manufacturer or importer of the finished product (including batch release or quality control testing sites)	20/08/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	24/06/25
Vet - F.II.b.3 h)	VRA-R - Vet - F.II.b.3 h) - h) Change in the holding time of an intermediate or bulk product (if applicable) - F.II.b.3 h) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Change in the holding time of an intermediate or bulk product (if applicable)	03/04/25
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	02/10/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of	01/12/23

	the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	
Vet - C10 a)	VNRA - Vet - C10 a) - a) Administrative information concerning the holder's representative - C10 a) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — administrative information concerning the holder's representative	03/11/23
Vet - C2	VNRA - Vet - C2 - Change(s) in the Summary of Product Characteristics (SPC), labelling or package leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6 - C2 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the Summary of Product Characteristics (SPC), labelling or package leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6	05/07/23
Vet - B12 c)	VNRA - Vet - B12 c) - c) Minor changes to an approved test procedure for an in-process test - B12 c) Changes to the quality part of the dossier: Minor changes — to an approved test procedure for an in-process test — for active substance; — for the finished product	24/03/23